| ELOVL6 promotes the progression of head and neck squamous cell carcinoma via activating WNT/beta-catenin pathway. | ELOVL6 promotes the progression of head and neck squamous cell carcinoma via activating WNT/β-catenin pathway.
Wang R, Liu X, Li X, Qian M, Yang X, Jiang Q, Wang Y, Liu H, Chen J, Wang X, Gong L. | 07/31/2024 |
| ELOVL6 is associated with immunosuppression in lung adenocarcinoma through bioinformatics analysis. | ELOVL6 is associated with immunosuppression in lung adenocarcinoma through bioinformatics analysis.
Chen B, Shen K, Zhang T, Gao WC., Free PMC Article | 09/22/2023 |
| 33 ELOVL6 mutations were found with a new variant in the promoter region, though no mutation in the coding region was found. However no mutations were found that largely deviated in allele frequency as compared with healthy Japanese individuals. | FADS2 and ELOVL6 mutation frequencies in Japanese Crohn's disease patients.
Motoi Y, Ito Z, Suzuki S, Takami S, Matsuo K, Sato M, Ota Y, Tsuruta M, Kojima M, Noguchi M, Uchiyama K, Kubota T. | 05/16/2020 |
| our results indicate that Elovl6 enhances oncogenic activity in liver cancer and is associated with poor prognosis in patients with HCC. Elovl6 may be a therapeutic target for HCC | Elovl6 is a negative clinical predictor for liver cancer and knockdown of Elovl6 reduces murine liver cancer progression.
Su YC, Feng YH, Wu HT, Huang YS, Tung CL, Wu P, Chang CJ, Shiau AL, Wu CL., Free PMC Article | 10/19/2019 |
| Functional screening...revealed ELOVL6 as the main elongation enzyme responsible for acyl chain elongation in lung cancer squamous cell carcinoma cancer cells | Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma.
Marien E, Meister M, Muley T, Gomez Del Pulgar T, Derua R, Spraggins JM, Van de Plas R, Vanderhoydonc F, Machiels J, Binda MM, Dehairs J, Willette-Brown J, Hu Y, Dienemann H, Thomas M, Schnabel PA, Caprioli RM, Lacal JC, Waelkens E, Swinnen JV., Free PMC Article | 12/9/2017 |
| Ultra-high-throughput fluorescence screening followed by a RapidFire mass spectrometry assay was a suitable strategy for lead discovery against Elovl6. | Lead discovery for mammalian elongation of long chain fatty acids family 6 using a combination of high-throughput fluorescent-based assay and RapidFire mass spectrometry assay.
Takamiya M, Sakurai M, Teranishi F, Ikeda T, Kamiyama T, Asai A. | 06/3/2017 |
| ). In conclusion, we found an interaction between the HLA-Cw6 and LCE genotypes on disease improvement among psoriatic patients treated with anti-TNFs. | The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients.
Batalla A, Coto E, González-Fernández D, González-Lara L, Gómez J, Santos-Juanes J, Queiro R, Coto-Segura P. | 01/30/2016 |
| KAR regulates ELOVL6 via two modes; KAR may induce conformational changes in ELOVL6; conversion of 3-ketoacyl-CoA to 3-hydroxyacyl-CoA by KAR may facilitate release of the product from the ELOVL6-KAR complex. | Two modes of regulation of the fatty acid elongase ELOVL6 by the 3-ketoacyl-CoA reductase KAR in the fatty acid elongation cycle.
Naganuma T, Kihara A., Free PMC Article | 10/24/2015 |
| human liver samples from patients with Non-alcoholic steatohepatitis or Non-alcoholic steatohepatitis-related hepatocellular carcinoma showed an elevated expression of the elongase ELOVL6, which is responsible for the elongation of C16 fatty acids. | Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma.
Kessler SM, Simon Y, Gemperlein K, Gianmoena K, Cadenas C, Zimmer V, Pokorny J, Barghash A, Helms V, van Rooijen N, Bohle RM, Lammert F, Hengstler JG, Mueller R, Haybaeck J, Kiemer AK., Free PMC Article | 01/24/2015 |
| The study indicated that the ELOVL6 gene polymorphism rs12504538 is associated with an increased risk of T2DM, because it causes an increase in insulin resistance. | Genetic analysis of the ELOVL6 gene polymorphism associated with type 2 diabetes mellitus.
Liu Y, Wang F, Yu XL, Miao ZM, Wang ZC, Chen Y, Wang YG., Free PMC Article | 10/4/2014 |
| Elovl6 expression is significantly downregulated in human lung with idiopathic pulmonary fibrosis. | Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice.
Sunaga H, Matsui H, Ueno M, Maeno T, Iso T, Syamsunarno MR, Anjo S, Matsuzaka T, Shimano H, Yokoyama T, Kurabayashi M. | 05/3/2014 |
| Elovl6 expression is positively correlated with severity of hepatosteatosis and liver injury in NASH patients. | Elovl6 promotes nonalcoholic steatohepatitis.
Matsuzaka T, Atsumi A, Matsumori R, Nie T, Shinozaki H, Suzuki-Kemuriyama N, Kuba M, Nakagawa Y, Ishii K, Shimada M, Kobayashi K, Yatoh S, Takahashi A, Takekoshi K, Sone H, Yahagi N, Suzuki H, Murata S, Nakamuta M, Yamada N, Shimano H. | 03/2/2013 |
| study showed cystic fibrosis cells exhibit increased metabolism along metabolic pathways leading to n-7 and n-9 fatty acids compared with wild-type cells; changes are accompanied by increased expression of Delta5, Delta6 and Delta9 desaturases and elongases 5 and 6 | Increased elongase 6 and Δ9-desaturase activity are associated with n-7 and n-9 fatty acid changes in cystic fibrosis.
Thomsen KF, Laposata M, Njoroge SW, Umunakwe OC, Katrangi W, Seegmiller AC., Free PMC Article | 11/24/2012 |
| Genetic variations in the ELOVL6 gene were associated with insulin sensitivity in this population-based study. | ELOVL6 genetic variation is related to insulin sensitivity: a new candidate gene in energy metabolism.
Morcillo S, Martín-Núñez GM, Rojo-Martínez G, Almaraz MC, García-Escobar E, Mansego ML, de Marco G, Chaves FJ, Soriguer F., Free PMC Article | 10/15/2011 |
| Studies suggest that inhibition of ELOVL6 could be a new therapeutic approach for the treatment of insulin resistance, diabetes, cardiovascular disease, and other metabolic diseases. | Elovl6: a new player in fatty acid metabolism and insulin sensitivity.
Matsuzaka T, Shimano H. | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (2) articlesA systematic gene-based screen of chr4q22-q32 identifies association of a novel susceptibility gene, DKK2, with the quantitative trait of alcohol dependence symptom counts.
Kalsi G, Kuo PH, Aliev F, Alexander J, McMichael O, Patterson DG, Walsh D, Zhao Z, Schuckit M, Nurnberger J Jr, Edenberg H, Kramer J, Hesselbrock V, Tischfield JA, Vladimirov V, Prescott CA, Dick DM, Kendler KS, Riley BP. Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations.
Lu Y, Dollé ME, Imholz S, van 't Slot R, Verschuren WM, Wijmenga C, Feskens EJ, Boer JM. | 09/24/2008 |